FDA reviewing NC biotech's treatment for age-related vision loss

The Research Triangle Park company expects a federal decision in October. It's also advancing gene therapy programs for ...
PharmiWeb

Eye Glasses Market Analysis by Key Drivers, Top Players, Forecast, Growth Rate, Constraints, Future Trends, Events, And Challenges Until 2030

The global eyeglasses market is projected to grow at a rate of 7% over the next five years, driven by several key factors. These include the rising prevalence of refractive errors and vision disorders ...

Report highlights dangers of red-light laser myopia therapy for children

As red-light laser therapy gains popularity in Asia for slowing myopia in children, reports of vision damage have emerged, ...
WRIC Richmond on MSN

Cornerstone Eye's new light therapy helps aging vision preservation

Cornerstone Eye Associates has become the first practice in Rochester to offer Valeda Light Therapy for the treatment of dry macular degeneration. The new Food and Drug Administration-approved ...
EurekAlert!

UH Professor warns of dangers of red-light laser myopia therapy for children

As red-light laser therapy gains popularity in Asia for slowing myopia in children, reports of vision damage have emerged, ...
Healio

Virtual reality in eye care will expand, augment physicians’ abilities

The primary applications of virtual reality in ophthalmology include physician and patient education, diagnostic testing in ...

Gene therapy is transforming lives, but for many Americans it's hard to reach

Gene therapies have the potential to cure some diseases, but they are extraordinarily expensive. Location can also be a big ...
Healio

Gene therapies may help patients maintain vision in wet AMD long term

The recent progress and future development of gene therapy could help patients with wet age-related macular degeneration maintain vision, according to a speaker at Retina 2026. Allen C. Ho, MD, of ...
Ophthalmology Times

Rare Disease Day: An abundance of research Is underway to address rare eye diseases

Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...

Luminopia Announces CareFirst BlueCross BlueShield Coverage for Its Pediatric Lazy Eye Treatment

The policy further expands access to Luminopia's engaging, FDA-cleared treatment for children with lazy eye CAMBRIDGE, Mass., Feb. 25, 2026 /PRNewswire/ -- Luminopia, Inc., a digital health company ...

Argenx Touts Positive Phase 3 Eye Disease Study Results

Argenx SE ARGX on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG). It is an autoimmune disorder where ...
JD Supra

The Eyes Have It: FDA Approves Phase 1 Clinical Trial of Life Biosciences’ Reprogramming Therapy for Vision Loss

The US Food and Drug Administration (FDA) has approved a Phase 1 clinical trial from Life Biosciences that aims to help certain eye cells act younger and improve vision in glaucoma and related ...